Autopsy report · NCT04990778

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“PI Request”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Sponsor type: University, hospital or other
Conditions: Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
Interventions: Eprenetapopt; Venetoclax
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.